
    
      This is a phase II, multicenter study to assess the efficacy and safety of SHC014748M, an
      oral inhibitor of PI3K delta, in patients with relapsed or refractory relapsed or refractory
      follicular (FL) or marginal one (MZL) lymphoma.
    
  